GENNIE MULLEN: Open Payments
NPI 1447802137 · CHANUTE, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$203 in 12 payments from 8 companies in 2025. Trend: 2023 $225 · 2024 $330 · 2025 $203
Food & beverage: $203
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| PFIZER INC. | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $15 |
| GlaxoSmithKline, LLC. | 1 | $14 |
| Novo Nordisk Inc | 1 | $14 |
Products named: FARXIGA, CAPLYTA, Leqembi, REXULTI, PREVNAR 20, LEQVIO, TRELEGY ELLIPTA, Ozempic.
Industry payments across KS — which companies pay providers there.
